Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This meta-analysis found that combined BRAF and MEK inhibitor treatment in melanoma patients is linked to increased all-grade rash but reduced risks of several other dermatological toxicities compared to BRAF inhibition alone.

This study found that patients with unresectable melanoma treated with AZD6244 experienced skin reactions, including depigmentation and papulopustular rashes, in patterns similar to those caused by EGFR inhibitors.

This study found that dermatologic adverse events are common in children taking MEK inhibitors, with selumetinib patients experiencing less severe reactions and a lower risk of dosage adjustments. Age was noted as a factor in the likelihood of specific skin reactions.

This study found that EGFR and MEK inhibitors may induce acneiform skin toxicities by interacting with the skin bacterium Cutibacterium acnes to increase IL-36γ and IL-8 production in keratinocytes.